These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 31639314)
1. Combination Therapy with Lumacaftor-Ivacaftor in Cystic Fibrosis. Keeping It Real. Sala MA; Jain M Am J Respir Crit Care Med; 2020 Jan; 201(2):133-134. PubMed ID: 31639314 [No Abstract] [Full Text] [Related]
2. Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis. Elborn JS; Ramsey BW; Boyle MP; Konstan MW; Huang X; Marigowda G; Waltz D; Wainwright CE; Lancet Respir Med; 2016 Aug; 4(8):617-626. PubMed ID: 27298017 [TBL] [Abstract][Full Text] [Related]
3. Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study. McNamara JJ; McColley SA; Marigowda G; Liu F; Tian S; Owen CA; Stiles D; Li C; Waltz D; Wang LT; Sawicki GS Lancet Respir Med; 2019 Apr; 7(4):325-335. PubMed ID: 30686767 [TBL] [Abstract][Full Text] [Related]
5. The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis. Talamo Guevara M; McColley SA Expert Opin Drug Saf; 2017 Nov; 16(11):1305-1311. PubMed ID: 28846049 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial. Ratjen F; Hug C; Marigowda G; Tian S; Huang X; Stanojevic S; Milla CE; Robinson PD; Waltz D; Davies JC; Lancet Respir Med; 2017 Jul; 5(7):557-567. PubMed ID: 28606620 [TBL] [Abstract][Full Text] [Related]
7. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. Konstan MW; McKone EF; Moss RB; Marigowda G; Tian S; Waltz D; Huang X; Lubarsky B; Rubin J; Millar SJ; Pasta DJ; Mayer-Hamblett N; Goss CH; Morgan W; Sawicki GS Lancet Respir Med; 2017 Feb; 5(2):107-118. PubMed ID: 28011037 [TBL] [Abstract][Full Text] [Related]
8. Real-Life Safety and Effectiveness of Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis. Burgel PR; Munck A; Durieu I; Chiron R; Mely L; Prevotat A; Murris-Espin M; Porzio M; Abely M; Reix P; Marguet C; Macey J; Sermet-Gaudelus I; Corvol H; Bui S; Lemonnier L; Dehillotte C; Da Silva J; Paillasseur JL; Hubert D; Am J Respir Crit Care Med; 2020 Jan; 201(2):188-197. PubMed ID: 31601120 [No Abstract] [Full Text] [Related]
9. Lumacaftor/Ivacaftor: A Review in Cystic Fibrosis. Deeks ED Drugs; 2016 Aug; 76(12):1191-201. PubMed ID: 27394157 [TBL] [Abstract][Full Text] [Related]
10. Effects of Lumacaftor-Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis. Graeber SY; Dopfer C; Naehrlich L; Gyulumyan L; Scheuermann H; Hirtz S; Wege S; Mairbäurl H; Dorda M; Hyde R; Bagheri-Hanson A; Rueckes-Nilges C; Fischer S; Mall MA; Tümmler B Am J Respir Crit Care Med; 2018 Jun; 197(11):1433-1442. PubMed ID: 29327948 [TBL] [Abstract][Full Text] [Related]
11. An "Unlikely" Pair: The Antimicrobial Synergy of Polymyxin B in Combination with the Cystic Fibrosis Transmembrane Conductance Regulator Drugs KALYDECO and ORKAMBI. Schneider EK; Azad MA; Han ML; Tony Zhou Q; Wang J; Huang JX; Cooper MA; Doi Y; Baker MA; Bergen PJ; Muller MT; Li J; Velkov T ACS Infect Dis; 2016 Jul; 2(7):478-88. PubMed ID: 27626100 [TBL] [Abstract][Full Text] [Related]
12. Effects of Lumacaftor/Ivacaftor in a Pediatric Cohort Homozygous for F508del-CFTR. Egan ME Am J Respir Crit Care Med; 2017 Apr; 195(7):849-850. PubMed ID: 28362199 [No Abstract] [Full Text] [Related]
13. An Observational Study of Outcomes and Tolerances in Patients with Cystic Fibrosis Initiated on Lumacaftor/Ivacaftor. Jennings MT; Dezube R; Paranjape S; West NE; Hong G; Braun A; Grant J; Merlo CA; Lechtzin N Ann Am Thorac Soc; 2017 Nov; 14(11):1662-1666. PubMed ID: 28406713 [TBL] [Abstract][Full Text] [Related]
14. Can lumacaftor-ivacaftor reverse glucose-tolerance abnormalities in cystic fibrosis? Kessler L J Cyst Fibros; 2020 Jul; 19(4):666. PubMed ID: 32387043 [No Abstract] [Full Text] [Related]
15. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. Wainwright CE; Elborn JS; Ramsey BW N Engl J Med; 2015 Oct; 373(18):1783-4. PubMed ID: 26510034 [No Abstract] [Full Text] [Related]
16. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. Rehman A; Baloch NU; Janahi IA N Engl J Med; 2015 Oct; 373(18):1783. PubMed ID: 26510035 [No Abstract] [Full Text] [Related]